The antitumor effects of oncolytic adenovirus H101 against lung cancer

Lei,Jie; Li,Qi-Hua; Yang,Ju-Lun; Liu,Feng; Wang,Li; Xu,Wen-Mang; Zhao,Wen-Xing

doi:10.3892/ijo.2015.3045

The antitumor effects of oncolytic adenovirus H101 against lung cancer

Authors:
- Jie Lei
- Qi-Hua Li
- Ju-Lun Yang
- Feng Liu
- Li Wang
- Wen-Mang Xu
- Wen-Xing Zhao
View Affiliations

Affiliations: Department of Pathology, Kunming General Hospital of PLA, Kunming, Yunnan 650032, P.R. China, College of Science and Technology, Yunnan Agriculture University, Kunming, Yunnan 650201, P.R. China, School of Life Sciences of Yunnan University, Kunming, Yunnan 650091, P.R. China
Published online on: June 11, 2015 https://doi.org/10.3892/ijo.2015.3045
Pages: 555-562

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is the leading cause of cancer mortality in both men and women, with dismal survival rates due to late-stage diagnoses and a lack of efficacious therapies. The new treatment options with completely novel mechanism of therapeutic activity are needed for lung cancer to improve patient outcome. The present study was aimed at testing the efficacy of recombinant adenovirus H101 as an oncolytic agent for killing human lung cancer cell lines in vitro and in vivo. We assessed the coxsackievirus adenovirus receptor (CAR) expression on human lung cancer cell lines by RT-PCR and immunocytochemistry staining. Viral infectivity and viral replication in lung cancer cells was assayed by flow cytometry and real-time fluorescent quantitative PCR. After H101 treatment, cytotoxic effect, cell cycle progression and apoptosis were further examined by lactate dehydrogenase release assay and flow cytometry in vitro, respectively. In vivo, antitumor effects of H101 were assessed on SCID Beige mice xenografted with human lung cancer cells. Receptor characterization confirmed that human lung cancer cell lines expressed CAR receptor for adenovirus type 5. Lung cancer cells were sensitive to infection by the H101 virus. H101 infection and replication resulted in very potent cytotoxicity, G2/M phase arrest and cell lysis. In vivo, we also showed that H101 significantly inhibited tumor growth following intratumoral injection, with virus replication, cell degeneration and necrosis in the tumor tissue. These results have important implications for the treatment of human lung cancer.

View Figures

View References

1	Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594. 2008. View Article : Google Scholar : PubMed/NCBI
2	Ramalingam SS, Owonikoko TK and Khuri FR: Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin. 61:91–112. 2011. View Article : Google Scholar : PubMed/NCBI
3	Roy M, Luo YH, Ye M and Liu J: Nonsmall cell lung cancer therapy: Insight into multitargeted small-molecule growth factor receptor inhibitors. BioMed Res Int. 2013:9647432013. View Article : Google Scholar : PubMed/NCBI
4	Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le Cesne A, Leahy MG, Radford JA, Van Glabbeke MM, Kirkpatrick A, Hogendoorn PC, et al; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 25:3144–3150. 2007. View Article : Google Scholar : PubMed/NCBI
5	Herbst RS, Heymach JV and Lippman SM: Lung cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI
6	Carrera S, Buque A, Azkona E, Aresti U, Calvo B, Sancho A, Arruti M, Nuño M, Rubio I, de Lobera AR, et al: Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: Biological basis and therapeutic strategies. Clin Transl Oncol. 16:339–350. 2014. View Article : Google Scholar
7	Jemal A, Center MM, DeSantis C and Ward EM: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 19:1893–1907. 2010. View Article : Google Scholar : PubMed/NCBI
8	Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
9	Pao W and Girard N: New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12:175–180. 2011. View Article : Google Scholar : PubMed/NCBI
10	Guo ZS, Thorne SH and Bartlett DL: Oncolytic virotherapy: Molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta. 1785:217–231. 2008.PubMed/NCBI
11	Jiang G, Yang CS, Xu D, Sun C, Zheng JN, Lei TC and Liu YQ: Potent antitumour activity of a novel conditionally replicating adenovirus for melanoma via inhibition of migration and invasion. Br J Cancer. 110:2496–2505. 2014. View Article : Google Scholar : PubMed/NCBI
12	Immonen A, Vapalahti M, Tyynelä K, Hurskainen H, Sandmair A, Vanninen R, Langford G, Murray N and Ylä-Herttuala S: AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: A randomised, controlled study. Mol Ther. 10:967–972. 2004. View Article : Google Scholar : PubMed/NCBI
13	Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, Gore M, Ironside J, MacDougall RH, Heise C, et al: A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 6:879–885. 2000. View Article : Google Scholar : PubMed/NCBI
14	Doloff JC and Waxman DJ: Adenoviral vectors for prodrug activation-based gene therapy for cancer. Anticancer Agents Med Chem. 14:115–126. 2014. View Article : Google Scholar :
15	Kawashima T, Kagawa S, Kobayashi N, Shirakiya Y, Umeoka T, Teraishi F, Taki M, Kyo S, Tanaka N and Fujiwara T: Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res. 10:285–292. 2004. View Article : Google Scholar : PubMed/NCBI
16	Kasuya H, Takeda S, Shimoyama S, Shikano T, Nomura N, Kanazumi N, Nomoto S, Sugimoto H and Nakao A: Oncolytic virus therapy - foreword. Curr Cancer Drug Targets. 7:123–125. 2007. View Article : Google Scholar : PubMed/NCBI
17	Zhang H, Wang H, Zhang J, Qian G, Niu B, Fan X, Lu J, Hoffman AR, Hu JF and Ge S: Enhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors. Mol Ther. 17:57–64. 2009. View Article : Google Scholar
18	Yan FC, Wang QQ, Ruan YH, Ma LJ, Jia JT and Jin KW: Establishment and biological characteristics of lung cancer cell line XWLC-05. Ai Zheng. 26:21–25. 2007.(In Chinese). PubMed/NCBI
19	Anders M, Christian C, McMahon M, McCormick F and Korn WM: Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells. Cancer Res. 63:2088–2095. 2003.PubMed/NCBI
20	Song X, Zhou Y, Jia R, Xu X, Wang H, Hu J, Ge S and Fan X: Inhibition of retinoblastoma in vitro and in vivo with conditionally replicating oncolytic adenovirus H101. Invest Ophthalmol Vis Sci. 51:2626–2635. 2010. View Article : Google Scholar
21	Zhang C, Awasthi N, Schwarz MA, Hinz S and Schwarz RE: Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer. PLoS One. 8:e580372013. View Article : Google Scholar : PubMed/NCBI
22	Liu TC and Kirn D: Gene therapy progress and prospects cancer: Oncolytic viruses. Gene Ther. 15:877–884. 2008. View Article : Google Scholar : PubMed/NCBI
23	Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, et al: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 274:373–376. 1996. View Article : Google Scholar : PubMed/NCBI
24	Post DE, Khuri FR, Simons JW and Van Meir EG: Replicative oncolytic adenoviruses in multimodal cancer regimens. Hum Gene Ther. 14:933–946. 2003. View Article : Google Scholar : PubMed/NCBI
25	Ranki T, Särkioja M, Hakkarainen T, von Smitten K, Kanerva A and Hemminki A: Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer. Int J Cancer. 121:165–174. 2007. View Article : Google Scholar : PubMed/NCBI
26	Rajecki M, Kanerva A, Stenman UH, Tenhunen M, Kangasniemi L, Särkioja M, Ala-Opas MY, Alfthan H, Sankila A, Rintala E, et al: Treatment of prostate cancer with Ad5/3Delta24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo. Mol Cancer Ther. 6:742–751. 2007. View Article : Google Scholar : PubMed/NCBI
27	Nemunaitis J, Tong AW, Nemunaitis M, Senzer N, Phadke AP, Bedell C, Adams N, Zhang YA, Maples PB, Chen S, et al: A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ther. 18:429–434. 2010. View Article : Google Scholar :
28	Yu W and Fang H: Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets. 7:141–148. 2007. View Article : Google Scholar : PubMed/NCBI
29	Freytag SO, Movsas B, Aref I, Stricker H, Peabody J, Pegg J, Zhang Y, Barton KN, Brown SL, Lu M, et al: Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Mol Ther. 15:1016–1023. 2007. View Article : Google Scholar : PubMed/NCBI
30	Yamamoto M, Davydova J, Wang M, Siegal GP, Krasnykh V, Vickers SM and Curiel DT: Infectivity enhanced, cyclooxy-genase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology. 125:1203–1218. 2003. View Article : Google Scholar : PubMed/NCBI
31	Ganly I, Kirn D, Eckhardt G, Rodriguez GI, Soutar DS, Otto R, Robertson AG, Park O, Gulley ML, Heise C, et al: A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res. 6:798–806. 2000.PubMed/NCBI
32	Anders M, Rösch T, Küster K, Becker I, Höfler H, Stein HJ, Meining A, Wiedenmann B and Sarbia M: Expression and function of the coxsackie and adenovirus receptor in Barrett’s esophagus and associated neoplasia. Cancer Gene Ther. 16:508–515. 2009. View Article : Google Scholar : PubMed/NCBI
33	Brüning A, Stickeler E, Diederich D, Walz L, Rohleder H, Friese K and Runnebaum IB: Coxsackie and adenovirus receptor promotes adenocarcinoma cell survival and is expressionally activated after transition from preneoplastic precursor lesions to invasive adenocarcinomas. Clin Cancer Res. 11:4316–4320. 2005. View Article : Google Scholar : PubMed/NCBI
34	Qin M, Escuadro B, Dohadwala M, Sharma S and Batra RK: A novel role for the coxsackie adenovirus receptor in mediating tumor formation by lung cancer cells. Cancer Res. 64:6377–6380. 2004. View Article : Google Scholar : PubMed/NCBI
35	Fuxe J, Liu L, Malin S, Philipson L, Collins VP and Pettersson RF: Expression of the coxsackie and adenovirus receptor in human astrocytic tumors and xenografts. Int J Cancer. 103:723–729. 2003. View Article : Google Scholar : PubMed/NCBI
36	Yamamoto M and Curiel DT: Current issues and future directions of oncolytic adenoviruses. Mol Ther. 18:243–250. 2010. View Article : Google Scholar :
37	Pesonen S, Kangasniemi L and Hemminki A: Oncolytic adenoviruses for the treatment of human cancer: Focus on translational and clinical data. Mol Pharm. 8:12–28. 2011. View Article : Google Scholar